IL155988A - Nuclear magnetic resonance method for screening compounds in order to identify ligands that bind to a specific target molecule - Google Patents

Nuclear magnetic resonance method for screening compounds in order to identify ligands that bind to a specific target molecule

Info

Publication number
IL155988A
IL155988A IL15598896A IL15598896A IL155988A IL 155988 A IL155988 A IL 155988A IL 15598896 A IL15598896 A IL 15598896A IL 15598896 A IL15598896 A IL 15598896A IL 155988 A IL155988 A IL 155988A
Authority
IL
Israel
Prior art keywords
target molecule
bind
specific target
ligand
magnetic resonance
Prior art date
Application number
IL15598896A
Other languages
English (en)
Other versions
IL155988A0 (en
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24218250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL155988(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of IL155988A0 publication Critical patent/IL155988A0/xx
Publication of IL155988A publication Critical patent/IL155988A/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
    • G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Compounds Of Iron (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL15598896A 1995-11-14 1996-11-13 Nuclear magnetic resonance method for screening compounds in order to identify ligands that bind to a specific target molecule IL155988A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/555,691 US5698401A (en) 1995-11-14 1995-11-14 Use of nuclear magnetic resonance to identify ligands to target biomolecules
IL12392396A IL123923A (en) 1995-11-14 1996-11-13 Nuclear magnetic resonance method for screening compounds in order to identify ligands that bind to a specific target molecule
PCT/US1996/018270 WO1997018471A1 (en) 1995-11-14 1996-11-13 Use of nuclear magnetic resonance to identify ligands to target biomolecules

Publications (2)

Publication Number Publication Date
IL155988A0 IL155988A0 (en) 2003-12-23
IL155988A true IL155988A (en) 2005-07-25

Family

ID=24218250

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15598896A IL155988A (en) 1995-11-14 1996-11-13 Nuclear magnetic resonance method for screening compounds in order to identify ligands that bind to a specific target molecule
IL12392396A IL123923A (en) 1995-11-14 1996-11-13 Nuclear magnetic resonance method for screening compounds in order to identify ligands that bind to a specific target molecule

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL12392396A IL123923A (en) 1995-11-14 1996-11-13 Nuclear magnetic resonance method for screening compounds in order to identify ligands that bind to a specific target molecule

Country Status (13)

Country Link
US (2) US5698401A (xx)
EP (2) EP0981049B1 (xx)
JP (1) JP3032301B2 (xx)
AT (2) ATE189063T1 (xx)
AU (1) AU701810B2 (xx)
CA (1) CA2237343C (xx)
DE (2) DE69606324T3 (xx)
DK (1) DK0866967T4 (xx)
ES (1) ES2143793T5 (xx)
GR (1) GR3032361T3 (xx)
IL (2) IL155988A (xx)
PT (1) PT866967E (xx)
WO (1) WO1997018471A1 (xx)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989827A (en) * 1995-11-14 1999-11-23 Abbott Laboratories Use of nuclear magnetic resonance to design ligands to target biomolecules
US20010004528A1 (en) * 1995-11-14 2001-06-21 Stephen W. Fesik Use of 13c nuclear magnetic resonance to detect binding to target molecules
IL126347A (en) 1996-03-29 2003-11-23 Lawrence Berkeley National Lab Enhancement of nmr and mri in the presence of hyperpolarized noble gases
DE19649359C1 (de) * 1996-11-28 1998-02-12 Thomas Prof Dr Peters Verfahren zum Nachweis biologisch aktiver Substanzen in Substanzbibliotheken
AU772620B2 (en) * 1997-04-18 2004-05-06 Abbvie Inc. Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules
US6043024A (en) * 1997-04-18 2000-03-28 Abbott Laboratories Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules
CA2292751A1 (en) * 1997-06-13 1998-12-17 Christopher A. Lepre Methods for identifying drug cores
US20030143757A1 (en) * 1997-06-13 2003-07-31 Jonathan Moore Methods for identifying drug cores
US6111066A (en) 1997-09-02 2000-08-29 Martek Biosciences Corporation Peptidic molecules which have been isotopically substituted with 13 C, 15 N and 2 H in the backbone but not in the sidechains
US6344330B1 (en) * 1998-03-27 2002-02-05 The Regents Of The University Of California Pharmacophore recombination for the identification of small molecule drug lead compounds
US20020131972A1 (en) * 1998-05-21 2002-09-19 Daniel Sem Multi-partite ligands and methods of identifying and using same
EP1085846A2 (en) * 1998-06-08 2001-03-28 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
JP2002534687A (ja) * 1998-12-30 2002-10-15 アメルシャム・パブリック・リミテッド・カンパニー 過分極を使用したｎｍｒ分光学アッセイ
TWI283659B (en) * 1999-04-09 2007-07-11 Abbott Lab Site-specific isotopically-labeled proteins, amino acids, and biochemical precursors therefor
US6897337B2 (en) * 1999-04-09 2005-05-24 Abbott Laboratories Site-specific isotopically-labeled proteins, amino acids, and biochemical precursors therefor
US6333149B1 (en) 1999-06-04 2001-12-25 Triad Biotechnology, Inc. NMR-solve method for rapid identification of bi-ligand drug candidates
US6171804B1 (en) 1999-07-12 2001-01-09 The Rockefeller University Method of determining interdomain orientation and changes of interdomain orientation on ligation
US7105310B1 (en) * 2000-07-19 2006-09-12 California Institute Of Technology Detection of biomolecules by sensitizer-linked substrates
AU6115300A (en) * 1999-07-19 2001-02-05 California Institute Of Technology Detection of biomolecules by sensitizer-linked substrates
CA2383559A1 (en) * 1999-08-23 2001-03-01 Polaris Pharmaceuticals, Inc. Inhibitors of binding between proteins and macromolecular ligands
JP2003510608A (ja) * 1999-09-29 2003-03-18 スミスクライン・ビーチャム・コーポレイション 標的生体分子と相互作用する化合物を同定するための一次元および多次元核磁気共鳴の使用法
WO2001023330A2 (en) * 1999-09-29 2001-04-05 Pharmacia & Upjohn Company Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules
US6677160B1 (en) 1999-09-29 2004-01-13 Pharmacia & Upjohn Company Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules
US6764858B2 (en) 1999-09-29 2004-07-20 Pharmacia & Upjohn Company Methods for creating a compound library
GB9925677D0 (en) * 1999-10-29 1999-12-29 Pharmacia & Upjohn Spa Use of double-quantum 1H-NMR spectroscopy for the identification of ligands interacting with target biomolecules
WO2001062688A2 (en) * 2000-02-25 2001-08-30 Wyeth Methods of structure-based drug design using ms/nmr
AU2001251502A1 (en) * 2000-04-17 2001-10-30 Pharmacia And Upjohn Company Nuclear magnetic resonance methods for identifying sites in papillomavirus e2 protein
GB0013115D0 (en) * 2000-05-31 2000-07-19 Imp College Innovations Ltd Biological materials and methods for use in the prevention or treatment of infections
US7146277B2 (en) * 2000-06-13 2006-12-05 James H. Prestegard NMR assisted design of high affinity ligands for structurally uncharacterized proteins
US6652833B2 (en) 2000-07-13 2003-11-25 The Regents Of The University Of California Functionalized active-nucleus complex sensor
US7061237B2 (en) * 2000-07-13 2006-06-13 The Regents Of The University Of California Remote NMR/MRI detection of laser polarized gases
US20030165431A1 (en) * 2000-07-13 2003-09-04 The Regents Of The University Of California Method for detecting macromolecular conformational change and binding information
JP5129424B2 (ja) 2000-09-27 2013-01-30 ユニヴェルシテイト レイデン リガンドの発見または薬物スクリーニング手段としてのｎｍｒ利用法
SE0003811D0 (sv) * 2000-10-20 2000-10-20 Pharmacia Ab Screening methods
WO2002050538A2 (en) * 2000-12-21 2002-06-27 Triad Therapeutics, Inc. Sea-trosy and related methods
BR0116792A (pt) * 2000-12-22 2004-02-17 Ortho Mcneil Pharm Inc Derivados de diamina de triazol substituìdos como inibidores de quinase
US6656694B2 (en) 2001-01-11 2003-12-02 Theravance, Inc. Method for identifying a ligand for a biological substrate
US7645569B2 (en) * 2001-01-26 2010-01-12 Board Of Regents, The University Of Texas System NMR detection of foreign PAS domain ligands
US20020172967A1 (en) * 2001-02-13 2002-11-21 Gadek Thomas R. Identification of non-covalent complexes by mass spectrometry
DE10119455B4 (de) * 2001-04-20 2010-12-16 Siemens Ag Verfahren zum Auswerten von Daten, die mittels der Magnetresonanztechnik erzeugt werden und spektroskopische Information beinhalten
DK2070939T3 (da) 2001-05-25 2014-06-23 Univ Duke Modulatorer af farmakologiske midler
AU2002312146A1 (en) * 2001-05-30 2002-12-09 Triad Therapeutics, Inc. Nuclear magnetic resonance-docking of compounds
US20030129672A1 (en) * 2001-08-29 2003-07-10 Dyer Richard Dennis Method for identifying metalloenzyme inhibitors
US7653490B2 (en) * 2001-09-10 2010-01-26 Triad Liquidating Company LLC Nuclear magnetic resonance assembly of chemical entities
DE10144661C2 (de) * 2001-09-11 2003-08-14 Forschungsverbund Berlin Ev Vorrichtung und Verfahren zur Zuordnung der NMR-Signale von Polypeptiden
US7179450B2 (en) * 2001-09-20 2007-02-20 Medi-Physics, Inc. Methods for in vivo evaluation of pulmonary physiology and/or function using NMR signals of polarized Xe
WO2003040400A2 (en) * 2001-11-06 2003-05-15 Message Pharmaceuticals, Inc. Methods for detecting and quantifying binding and inhibition of binding of species to nucleic acids
DE10160177A1 (de) * 2001-12-07 2003-06-26 Novaspin Biotech Gmbh Verfahren zur Auffindung von Liganden die an ein drug target binden mittels 1H,1H-Kernresonanzspektroskopie
US20040171062A1 (en) * 2002-02-28 2004-09-02 Plexxikon, Inc. Methods for the design of molecular scaffolds and ligands
US20030180797A1 (en) * 2002-03-20 2003-09-25 Lin Yu Identification of ligands for a receptor family and related methods
AU2003253589A1 (en) * 2002-03-26 2003-11-10 Centocor, Inc. Epitope mapping using nuclear magnetic resonance
DE10221158A1 (de) * 2002-05-13 2004-02-19 Novaspin Biotech Gmbh Verfahren zur Auffindung von Liganden, die an ein drug target binden, mittels heteronuklearer Kernresonanzspektroskopie
JP2005528915A (ja) * 2002-06-10 2005-09-29 プロスペクト ファーマ タンパク質およびタンパク質／リガンド複合体に関するダイナミックおよび構造データを得る方法
CA2503905A1 (en) * 2002-09-16 2004-03-25 Plexxikon, Inc. Crystal structure of pim-1 kinase
WO2006078228A1 (en) * 2002-09-16 2006-07-27 Plexxikon, Inc. Methods for the design of molecular scaffolds and ligands
US20040132102A1 (en) * 2002-10-29 2004-07-08 Maurizio Pellecchia Use of selective labeling to detect and characterize molecular interactions by nuclear magnetic resonance spectroscopy
NO20025738D0 (no) 2002-11-29 2002-11-29 Amersham Health As Metode
WO2004078923A2 (en) * 2003-02-28 2004-09-16 Plexxikon, Inc. Pyk2 crystal structure and uses
US7964534B2 (en) * 2003-03-13 2011-06-21 Triad Liquidating Company, Llc Nuclear magnetic resonance assembly of chemical entities using advanced antenna probes
EP1623216A2 (en) * 2003-04-11 2006-02-08 SGX Pharmaceuticals, Inc. Compound libraries and methods for drug discovery
WO2004095028A1 (ja) * 2003-04-23 2004-11-04 Olympus Corporation 受容体に結合可能な物質をスクリーニングする方法
JP2004331832A (ja) * 2003-05-08 2004-11-25 Ricoh Co Ltd Ｄｎａインク組成物とそれを用いた識別画像印刷体、及びインクジェット記録装置
US20050079548A1 (en) * 2003-07-07 2005-04-14 Plexxikon, Inc. Ligand development using PDE4B crystal structures
US7255985B2 (en) * 2003-07-10 2007-08-14 Pfizer Italia S.R.L. Fluorine NMR spectroscopy for biochemical screening
WO2005028624A2 (en) * 2003-09-15 2005-03-31 Plexxikon, Inc. Molecular scaffolds for kinase ligand development
EP1678198A4 (en) * 2003-10-07 2007-12-05 Prospect Pharma SIDE CHAIN DEUTERATED AMINO ACIDS AND METHOD OF USE
JP4192078B2 (ja) * 2003-11-26 2008-12-03 株式会社日立製作所 核磁気共鳴方法
US7904252B2 (en) * 2003-11-28 2011-03-08 Hitachi, Ltd. Method for measuring a structural change in a protein
GB0405330D0 (en) * 2004-03-10 2004-04-21 Astrazeneca Ab Enzyme and preparation method
WO2006033962A2 (en) 2004-09-20 2006-03-30 Wisconsin Alumni Research Foundation Nonlinear spectroscopic methods for identifying and characterizing molecular interactions
JPWO2006082963A1 (ja) * 2005-02-07 2008-06-26 三菱化学株式会社 標的分子とリガンドあるいはリガンド候補化合物との結合検出方法
WO2007105094A1 (en) 2006-03-14 2007-09-20 Universität Basel Method for the identification of new leads for drug candidates
US8933209B2 (en) 2006-04-26 2015-01-13 Abbvie Inc. Dep2 and its uses in major depressive disorder and other related disorders
US7760342B2 (en) 2007-12-21 2010-07-20 Wisconsin Alumni Research Foundation Multidimensional spectrometer
WO2012108297A1 (ja) * 2011-02-07 2012-08-16 国立大学法人 神戸大学 Ras部分ポリペプチド含有水溶液及びRas機能阻害剤のスクリーニング方法
ES2641325T3 (es) 2012-01-26 2017-11-08 Christopher J. Soares Antagonistas peptídicos de la familia calcitonina CGRP de hormonas peptídicas y su uso
AU2016305299B2 (en) 2015-08-11 2021-03-11 Arch Biopartners, Inc. DPEP-1 binding compositions and methods of use
US11390654B2 (en) 2016-09-02 2022-07-19 Christopher Joseph Soares Use of CGRP receptor antagonists in neuroprotection and neurological disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE904705A1 (en) * 1989-12-29 1991-07-17 Univ Technologies Int Methods for modelling tertiary structures of biologically¹active ligands including agonists and antagonists thereto¹and novel synthetic antagonists based on angiotensin
US5164297A (en) * 1990-05-03 1992-11-17 Advanced Magnetics Inc. Solvent mediated relaxation assay system
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5726014A (en) * 1991-06-27 1998-03-10 Genelabs Technologies, Inc. Screening assay for the detection of DNA-binding molecules
AU655839B2 (en) * 1991-06-27 1995-01-12 Genelabs Technologies, Inc. Screening assay for the detection of DNA-binding molecules

Also Published As

Publication number Publication date
AU701810B2 (en) 1999-02-04
JPH11513498A (ja) 1999-11-16
IL155988A0 (en) 2003-12-23
DE69606324T3 (de) 2008-02-07
EP0866967B2 (en) 2007-08-08
DE69631842D1 (de) 2004-04-15
JP3032301B2 (ja) 2000-04-17
PT866967E (pt) 2000-04-28
EP0866967B1 (en) 2000-01-19
GR3032361T3 (en) 2000-04-27
ATE261581T1 (de) 2004-03-15
ES2143793T3 (es) 2000-05-16
AU7732896A (en) 1997-06-05
DE69606324T2 (de) 2000-07-06
DK0866967T4 (da) 2007-12-10
US5804390A (en) 1998-09-08
EP0981049A1 (en) 2000-02-23
CA2237343C (en) 2009-01-20
DK0866967T3 (da) 2000-06-26
WO1997018471A1 (en) 1997-05-22
CA2237343A1 (en) 1997-05-22
IL123923A (en) 2005-07-25
EP0981049B1 (en) 2004-03-10
MX9803810A (es) 1998-09-30
US5698401A (en) 1997-12-16
ES2143793T5 (es) 2008-03-01
DE69606324D1 (de) 2000-02-24
EP0866967A1 (en) 1998-09-30
ATE189063T1 (de) 2000-02-15

Similar Documents

Publication Publication Date Title
IL155988A0 (en) A nuclear magnetic resonance method for screening compounds in order to identify ligands that bind to a specific target molecule
CA2653959A1 (en) Method for identifying ligands
GR3036454T3 (en) Use of nuclear magnetic resonance to design ligands to target biomolecules
EP0975954B1 (en) Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules
FR2649526B1 (fr) Procede de fabrication de tetes magnetiques planaires par alveolage d'une plaquette non magnetique, et tetes magnetiques obtenues par un tel procede
WO1990010709A3 (en) Monoclonal antibodies for metallic cations on small molecules
CA2176053A1 (en) Method and Apparatus for Agglutination Immunoassay
CA2178642A1 (en) Metal ion-ligand coordination complexes, antibodies directed thereto, and assays using such antibodies
GB9521943D0 (en) Coded particles for process sequence tracking in combinatorial compound library preparation
DE69606379D1 (de) Offener kryogengekühlter supraleitender Magnet für die Bilderzeugung durch magnetische Resonanz
DE59007200D1 (de) Verfahren zur Bestimmung eines Analyten.
FR2645954B1 (fr) Procede de determination d'une position utilisant des satellites
EP0638816A3 (en) Flow measurement using a magnetic resonance imaging method with difference of complex values.
DE69025351D1 (de) Durch Ätzen hergestellte Gradientenspule in Z-Achsenrichtung, für ein magnetisches Kernresonanz-System
Juarez-Garcia et al. Combined Moessbauer and EPR studies of the S= 3 state of an exchange-coupled iron (III)-copper (II) complex: test for quantitative EPR analysis of integer spin systems
DE59107957D1 (de) Verfahren für die zweidimensionale Kernresonanzspektroskopie
DE69100611D1 (de) Kompakte Sonde für die magnetische Kernresonanz.
FR2697930B1 (fr) Procédé de réalisation d'une image de référence synthétisée pour l'inspection d'objets.
CA2237336A1 (en) Use of nuclear magnetic resonance to design ligands to target biomolecules
FR2693813B1 (fr) Procédé de réalisation d'une image de référence synthétisée à partir de données contenues dans une base de données CAO.
FR2669137B1 (fr) Procede de reconnaissance d'objets tridimensionnels par analyse d'image.
FR2709851B1 (fr) Procédé de reconstruction d'une image tridimensionnelle par histoprojections.
FR2704322B1 (fr) Système de bobines de gradient transverse pour appareil de résonance magnétique nucléaire.
Ming et al. Proton nuclear magnetic resonance studies of iron (II/III)-amide complexes. Spectroscopic models for nonheme iron proteins [Erratum to document cited in CA113 (12): 107833c]
Thomas Electromagnetic Forming--an Elegant and Easily Reproducible Technique for Forming Metals on a Large Series Production Scale

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired